Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 38 (Search time: 0.004 seconds).
previous
1
2
3
4
next
Item hits:
Preview
Issue Date
Title
Author(s)
2017
Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia
Sopper, S.
;
Mustjoki, S.
;
White, D.
;
Hughes, T.
;
Valent, P.
;
Burchert, A.
;
Gjertsen, B.
;
Gastl, G.
;
Baldauf, M.
;
Trajanoski, Z.
;
Giles, F.
;
Hochhaus, A.
;
Ernst, T.
;
Schenk, T.
;
Janssen, J.
;
Ossenkoppele, G.
;
Porkka, K.
;
Wolf, D.
2014
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, T.
;
Saglio, G.
;
Kantarjian, H.
;
Guilhot, F.
;
Niederwieser, D.
;
Rosti, G.
;
Nakaseko, C.
;
De Souza, C.
;
Kalaycio, M.
;
Meier, S.
;
Fan, X.
;
Menssen, H.
;
Larson, R.
;
Hochhaus, A.
2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
Hughes, T.
;
Lipton, J.
;
Spector, N.
;
Cervantes, F.
;
Pasquini, R.
;
Clementino, N.
;
Dorlhiac Llacer, P.
;
Schwarer, A.
;
Mahon, F.
;
Rea, D.
;
Branford, S.
;
Purkayastha, D.
;
Collins, L.
;
Szczudlo, T.
;
Leber, B.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2016
Chronic myeloid leukemia: reminiscences and dreams
Mughal, T.
;
Radich, J.
;
Deininger, M.
;
Apperley, J.
;
Hughes, T.
;
Harrison, C.
;
Gambacorti-Passerini, C.
;
Saglio, G.
;
Cortes, J.
;
Daley, G.
2013
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients
Hughes, T.
;
White, D.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
Blake, S.
;
Hughes, T.
;
Lyons, A.
2009
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
Fraser, C.
;
Blake, S.
;
Diener, K.
;
Lyons, A.
;
Brown, M.
;
Hughes, T.
;
Hayball, J.
2009
Predicting the response of CML patients to tyrosine kinase inhibitor therapy
White, D.
;
Hughes, T.
Discover
Author
13
White, D.
11
Hochhaus, A.
9
Branford, S.
9
Radich, J.
9
Saglio, G.
8
Kantarjian, H.
7
Cortes, J.
5
Guilhot, F.
5
Kim, D.
5
Larson, R.
.
next >
Subject
34
Humans
33
Pyrimidines
29
Leukemia, Myelogenous, Chronic, B...
25
Benzamides
25
Piperazines
24
Imatinib Mesylate
20
Antineoplastic Agents
13
Fusion Proteins, bcr-abl
12
Treatment Outcome
10
Dasatinib
.
next >
Date issued
27
2010 - 2017
11
2005 - 2009